| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8651026 | American Heart Journal | 2018 | 10 Pages |
Abstract
Black patients are modestly represented among pivotal RCTs of individuals with HFrEF for both pharmacotherapies and implantable cardioverter defibrillators. The current trend for decreasing black representation in trials of HF therapeutics is concerning and must improve to ensure the generalizability for this vulnerable population.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Lonnie T. BS, Tiffany MD, Peter PhD, Larry R. MD, Chidiebube MD, MPH, Monique A. MD, MHS, Kevin L. MD,